A few months ago, the team published the Fed AI Market, 2026–2028 report to shed light on the key drivers and trends shaping the evolving federal AI landscape. The report examined a wide range of AI policy developments since January. Among the most significant was the AI Action Plan, which outlined the Trump Administration’s strategic approach to federal AI adoption.

AI remains a priority for federal technology leaders across agencies. Understandably, since the release of Deltek’s report, several new AI policy developments have emerged. This article highlights key AI-related activities and updates that have taken place since August.

MOU Between the U.S. and the U.K.

In September, the U.S. and United Kingdom signed a Memorandum of Understanding on science and technology focus areas of mutual interest. In it, the MOU outlines a collaboration among the nations to accelerate AI innovation. Specifically, the participants agree to collaborate on building AI infrastructure, aiding researchers with access to compute capabilities, and supporting the creation of new scientific datasets in joint Flagship Research programs between U.S. research agencies (DOE, NSF, NIH and ARPA-H) and the U.K.’s counterpart agencies.

AI and Pediatric Cancer

In a September Executive Order (EO), Unlocking Cures for Pediatric Cancer with Artificial Intelligence, the White House bolsters support and investment for combatting childhood cancer diseases. The EO directs the MAHA Commission to develop ways to leverage technologies such as AI to improve diagnoses, treatments, cures and prevention methodologies.

Activities to achieve this mission include consolidating data from multiple resources for AI analysis, enhancing data analysis of complex biologic systems with AI tools, and incorporating multimodal data with AI to maximize analysis from clinical trials. The EO calls for increased investment from federal funds for the Childhood Cancer Data Initiative (CCDI) to ensure data availability for the initiative. CCDI is a program launched in 2019 at the National Cancer Institute to collect, generate and analyze childhood cancer data.

RFI on AI Regulation Inhibitors

The OSTP issued a Request for Information (RFI) seeking input on regulations that prevent AI innovation and adoption. The RFI is specifically seeking responses from the private sector and the public at large on Federal regulations that slow safe, beneficial AI deployment. Identified requirements include those that are considered regulatory mismatches, structurally incompatible, lack clarity, present a direct hindrance, or barriers stemming from organizational factors. Responses to the RFI are due no later than October 27, 2025.

Additional OneGov Deals

The OneGov Strategy calls on GSA to develop direct relationships with Original Equipment Manufacturers, to ensure cost efficiency and effectiveness for federal agencies. Since announcement of the strategy in April 2025, several software companies have made deals under the OneGov umbrella with special pricing for the federal government. Deals include AI solutions such as OpenAI’s ChatGPT, Anthropic’s Claude, and Box’s Enterprise Plus tools.

Last month, GSA secured two additional agreements aimed at accelerating federal access to AI solutions. Through a deal with ServiceNow, federal customers may receive discounts ranging from 40% to 70% on upgrades to the company’s AI platform. In a separate agreement with xAI, GSA announced a federal sale price of $0.42 for access to xAI’s Grok AI models. According to GSA, these agreements will accelerate access to AI models at competitive prices to accelerate federal AI adoption.